期刊
PROTEIN & CELL
卷 8, 期 12, 页码 896-925出版社
OXFORD UNIV PRESS
DOI: 10.1007/s13238-017-0400-z
关键词
chimeric antigen receptor; CAR-T; engineered T cells; adoptive cell therapy; cancer treatment
类别
资金
- National Natural Science Foundation of China [81230061]
- Science and Technology Planning Project of Beijing City [Z151100003915076]
- National Key Research and Development Program of China [2016YFC1303501, 2016YFC1303504]
Chimeric antigen receptor (CAR) is a recombinant immunoreceptor combining an antibody-derived targeting fragment with signaling domains capable of activating cells, which endows T cells with the ability to recognize tumor-associated surface antigens independent of the expression of major histocompatibility complex (MHC) molecules. Recent early-phase clinical trials of CAR-modified T (CAR-T) cells for relapsed or refractory B cell malignancies have demonstrated promising results (that is, anti-CD19 CAR-T in B cell acute lymphoblastic leukemia (B-ALL)). Given this success, broadening the clinical experience of CAR-T cell therapy beyond hematological malignancies has been actively investigated. Here we discuss the basic design of CAR and review the clinical results from the studies of CAR-T cells in B cell leukemia and lymphoma, and several solid tumors. We additionally discuss the major challenges in the further development and strategies for increasing anti-tumor activity and safety, as well as for successful commercial translation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据